QuidelOrtho Corporation is a diagnostics company providing testing solutions across clinical chemistry, immunoassay, molecular diagnostics, point-of-care, and transfusion medicine. The company operates through four main business units: Labs, which includes clinical chemistry and immunoassay instruments and tests; Molecular Diagnostics, offering PCR and sample-to-result systems; Point of Care, providing rapid testing for professional and over-the-counter use; and Transfusion Medicine, covering immunohematology and donor screening. QuidelOrtho serves customers globally, including hospitals, clinical laboratories, physician offices, blood banks, and retail clinics. The company was formed by the merger of Quidel Corporation and Ortho Clinical Diagnostics, combining an 80-year history of innovation in diagnostic science. Key products include the VITROS platform, SOFIA molecular testing systems, QUICKVUE rapid tests, and ORTHO VISION automated immunohematology systems. QuidelOrtho also offers informatics solutions such as the RESULTS MANAGER system and VITROS Automation Solutions to support laboratory operations.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage quidelortho.com
Sector Healthcare IR page ir.quidelortho.com/home/default.aspx
Tags
clinical chemistry, immunoassay, molecular diagnostics, point-of-care testing, transfusion medicine, immunohematology, donor screening, rapid testing, laboratory automation, informatics, ADENOPLUS, BIOVUE, FRESHCELLS, INFLAMMADRY, LYRA, METERPRO, MICROVUE, ORTHO, Ortho Clinical Diagnostics, ORTHO OPTIX, ORTHO VERSEIA, ORTHO VISION, QUICKVUE, QUIDEL, QuidelOrtho, QuidelOrtho AUTOMATION ROUTING, QuidelOrtho PERFORMANCE MANAGER, QuidelOrtho RESULTS MANAGER, SAVANNA, SOFIA, SOLANA, THYRETAIN, TRIAGE, VALUMETRIX, VIRENA, VITROS, VITROS XT, VITROS Results Management, VITROS Automation Solutions, D3, ORTHO CONNECT, READYCELLS, MicroTip Partnership Assays, Lex Diagnostics
Press page —

Metrics

Valuation  
Market cap $ 723.044M
Market cap (USD) $ 723.044M
P/E -1.94
PEG —
P/BV 0.40
P/S 0.28
P/OCF 91.52
P/FCF -6.13
Dividend yield —
Turnover / mcap —
Returns  
ROE -46.1%
ROI -23.6%
ROIC -14.4%
Profit margin -41.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 149.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -70.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Revenue 2.73B 2.783B 2.998B 3.266B 1.699B 1.662B 534.89M 522.285M 277.743M 191.603M 196.129M 182.615M 175.41M 153.289M 158.603M 113.339M 164.282M 128.132M 118.065M 106.015M 92.299M 78.691M 95.105M 76.273M 74.055M
Net profit -1.132B -2.052B -10.1M 548.7M 704.226M 810.287M 72.921M 74.183M -8.165M -13.808M -6.079M -7.074M 7.39M 4.993M 7.633M -11.271M 32.883M 18.848M 13.631M 21.718M -9.259M -6.287M 19.651M 1.291M 192K
Free cash flow -83M -112.1M 70.9M 744.4M 513.145M 564.836M 107.256M 104.656M 10.199M -94K 19.341M 24.537M 4.861M 7.412M 42.477M -16.698M 65.993M 24.823M 24.233M 16.262M -1.935M — 16.328M 1.895M 31K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001
Share price 28.56 44.55 73.7 85.67 141.88 192.25 70 61.51 45 23 22 28.24 25.31 18.23 17.09 11.25 14.98 14.58 19.96 13.87 — — — — —
Price performance 12m -0.36 -0.4 -0.14 -0.4 -0.26 1.75 0.14 0.37 0.96 0.05 -0.22 0.12 0.39 0.07 0.52 -0.25 0.03 -0.27 0.44 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 25M 67M 58.7M 94.5M 498M 378M 454M 303M 282M 417M
↳ YoY growth +35.8% +168.3% -12.5% +61.0% +426.7% -24.1% +20.1% -33.2% -6.9% +47.7%
↳ 5y CAGR +11.3% +15.5% +14.4% +22.4% +93.4% +72.2% +46.6% +38.9% +24.5% -3.5%
Borrowings, current (USD) 0.00 10.2M 0.00 — — 300,000 208M 140M 342M 178M
Borrowings, non-current (USD) 144M 227M 0.00 — — 700,000 2.64B 2.27B 2.14B 2.47B
Lease liabilities (USD) — — 90M 104M 113M 139M 212M 200M 198M 184M
Cash and deposits (USD) 170M 36.1M 43.7M 52.8M 490M 803M 293M 119M 98.3M 170M
Intangible assets (USD) 27.6M 204M 175M 148M 122M 98.7M 3.12B 2.93B 2.74B 2.56B
Right-of-use assets (USD) — — 87M 92.1M 101M 128M 181M 170M 169M 156M
Net debt (borrowings + leases - cash) (USD) -25.2M 201M 46.3M — — -663M 2.76B 2.5B 2.58B 2.66B
Cash flow detail
Operating cash flow (USD) 11.8M 27.7M 136M 134M 630M 806M 885M 280M 83M 105M
Purchases of property, plant and equipment (USD) -11.9M -17.5M -31.7M -27.2M -64.9M -293M -141M -209M -195M -188M
Change in receivables (cash effect) (USD) -6.27M -42.1M 8.24M -36.1M -402M 119M 150M 160M 5.4M -118M
Change in inventories (cash effect) (USD) 859,000 362,000 -3.97M 9.14M -54.9M -85M -117M -212M -134M -148M
Change in payables (cash effect) (USD) 4.32M 13M -331,000 2.43M 52.2M 10.4M 23.5M 3M -23.4M 40M
Share buybacks (cash effect) (USD) -20.2M -541,000 -4.34M -10.7M -47.9M -103M -74.3M -7.2M 0.00 0.00
Interest paid (cash effect) (USD) -6.49M -9.14M -7.93M -2.3M -480,000 0.00 -95.1M -150M -178M -172M
Income taxes paid (cash effect) (USD) -490,000 -1.27M -6.92M -2.19M -110M -236M -265M -86.6M -41.6M 25.4M
Share-based compensation (USD) 7.99M 9.06M 11.7M 13.3M 21M 25.4M 48.4M 51.6M 42.1M 45.9M
Operating cash flow before change in receivables (USD) 18.1M 69.8M 128M 171M 1.03B 687M 735M 120M 77.6M 223M
Free cash flow (OCF - PPE - intangibles) (USD) -94,000 10.2M 105M 107M 565M 513M 744M 70.9M -112M -83M
Income detail
Research and development expense (USD) 38.7M 33.6M 51.6M 52.6M 84.3M 95.7M 191M 247M 219M 186M
↳ 5y CAGR +8.0% +4.0% +8.6% +6.7% +18.9% +19.9% +41.4% +36.7% +33.0% +17.2%
Total comprehensive income (USD) -13.8M -8.11M 74M 72.6M 810M 705M 481M 27.5M -2.06B -1.11B
Comprehensive income to owners (USD) -13.8M -8.11M 74M 72.6M 810M 705M 481M 27.5M -2.06B -1.11B
Reported Feb 27, 2018 Feb 27, 2018 Feb 15, 2019 Feb 13, 2020 Feb 19, 2021 Aug 5, 2022 Feb 23, 2023 Feb 29, 2024 Feb 27, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 3, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release (the “Press Release”) announcing the financial results for its third quarter ended September 27, 2026, and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 3, 2026 to discuss such results. A copy of the Press Release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

As reported in the Press Release, QuidelOrtho has initiated a cost transformation and enterprise restructuring program (the “Restructuring Plan”) designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. In connection with the Restructuring Plan, effective November 9, 2026 (the “Effective Date”), the QuidelOrtho Board of Directors (the “Board”) has appointed Jonathan Siegrist, PhD to serve in the newly created role of Head of Point of Care Diagnostics and Bryan Hanson to serve in the newly created role of Head of Core Diagnostics.

11/03/2026

Download this Press Release PDF Format (opens in new window)

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―

― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―

― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026.

QuidelOrtho Corporation

**Key Third Quarter 2026 Results:
**(all comparisons are to the prior year period)

  • Total revenue was $619 million, a decrease of 12% both as reported and in constant currency. Excluding respiratory, China, and the U.S. Donor Screening business, total revenue grew 2% as reported and 3% in constant currency, reflecting the underlying strength of the business.

    • Labs revenue of $353 million declined 6% both as reported and in constant currency, primarily due to lower sales in China related to recently announced changes to In Vitro Diagnostics pricing. Outside China, Labs revenue grew 3% as reported and 4% in constant currency, driven by continued strength across the business.

    • Immunohematology revenue of $142 million was flat as reported and increased 1% in constant currency. Outside China, Immunohematology revenue grew 2% as reported and 3% in constant currency.

    • Point of Care revenue of $120 million declined 27% both as reported and in constant currency due to a softer respiratory season.

  • GAAP net loss was $54 million; GAAP operating loss was $8 million; adjusted EBITDA was $148 million.

  • GAAP net loss margin was 8.7%; GAAP operating loss margin was 1.2%; adjusted EBITDA margin was 23.9%.

  • GAAP diluted loss per share was $0.78; adjusted diluted earnings per share ("EPS") was $0.31.

  • Operating cash flow was $20 million; free cash flow was $0.3 million.

"The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program. This program is designed to improve profitability and cash flow while evolving our operating model around the distinct needs of our customers and markets. We believe these actions will help mitigate near-term headwinds and position the Company for sustainable long-term growth." 

Cost Transformation and Restructuring Program

The Company has initiated a new cost transformation and enterprise restructuring program designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. The Company expects the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.

Full-year 2026 Financial Guidance

Based on its current business outlook, the Company is updating its full-year financial guidance below:  

Full-year 2026 Financial Guidance As of 11/3/2026 As of 8/6/2026
Total revenues (reported) $2.52 - $2.54 billion $2.52 - $2.60 billion
Adjusted EBITDA $540 - $545 million $540 - $560 million
Adjusted EBITDA margin ~21% 21% - 22%
Adjusted diluted EPS $0.65 - $0.70 $0.65 - $0.90

Please see page 8 of the Third Quarter 2026 Financial Results presentation on the "Investor Relations" page of the Company's website for the full list of assumptions on which the Company's current 2026 financial guidance is based.

A reconciliation of forward-looking non-GAAP measures, including adjusted EBITDA, adjusted EBITDA margin and adjusted diluted EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. We are not, without unreasonable effort, able to reliably predict the impact of impairment charges and related tax benefits and other non-recurring adjustments. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. In addition, the Company believes any such reconciliation would imply a degree of precision and certainty that could be confusing to investors. See "Forward-Looking Statements" and "Non-GAAP Financial Measures."

Conference Call Information

QuidelOrtho will hold a conference call and webcast today beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the live webcast on the "Investor Relations" page of the Company's website at https://ir.quidelortho.com/events-and-presentations . A replay of the webcast will be available shortly after the event on the Company's website.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com  and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho's commercial and other strategic goals, financial guidance for 2026 and related assumptions and other future financial condition and operating results, including growth expectations and expected results of operations, financial position or cost-savings and operational improvement initiatives, including the expected results and anticipated benefits of the cost transformation and enterprise restructuring program and the timing and amount of related charges, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words "may," "will," "could," "would," "should," "might," "expect," "anticipate," "believe," "estimate," "plan," "intend," "goal," "project," "strategy," "future," "continue," "aim," "strive," "seek" or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results or outcomes to differ from those set forth or implied in the forward-looking statements: fluctuations in demand for QuidelOrtho's non-respiratory and respiratory products; supply chain, production, logistics, distribution and labor disruptions and challenges; inability to successfully identify, consummate or realize the anticipated benefits of strategic transactions, strategic restructurings, divestitures, spin-offs or discontinuances of certain business operations, or debt financings, on the anticipated timelines, or at all; delays in the development of or failures or delays in the receipt of approvals for new or enhanced products; failure of new products and services to be commercially viable or accepted; changes in reimbursement rates for our products, including reimbursement rate reductions by the China National Health Security Administration; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those arising from the effects of announced or future or amended tariffs, trade policies, investigations, global trade relations and other tariff-related developments, as well as those discussed in QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 28, 2025 and subsequent reports filed with the Securities and Exchange Commission (the "Commission"), including under Part I, Item 1A, "Risk Factors" of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Non-GAAP Financial Measures

This press release contains financial measures that are considered non-GAAP financial measures under applicable rules and regulations of the Commission, including but not limited to "constant currency total revenue changes," "constant currency total revenue changes, excluding respiratory, China and the U.S. Donor Screening business," "constant currency Labs revenue changes," "constant currency Labs revenue changes, excluding China," "constant currency Immunohematology revenue changes," "constant currency Immunohematology revenue changes, excluding China," "constant currency Point of Care revenue changes," "adjusted EBITDA," "adjusted EBITDA margin," "adjusted diluted EPS," "free cash flow" and other non-GAAP financial measures included in the reconciliation tables accompanying this press release. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results and comparison to competitors' operating results. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the historical non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

Investor Contact:
Sanjeev Sharma
Vice President, Investor Relations
[email protected]

Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
[email protected]

**QuidelOrtho **Consolidated Statements of Loss (Unaudited) (In millions, except per share data)
Three Months Ended Nine Months Ended
September 27, 2026 September 28, 2025 September 27, 2026 September 28, 2025
Total revenues $        618.9 $        699.9 $     1,869.6 $     2,006.6
Cost of sales, excluding amortization of intangibles 329.3 364.3 1,043.3 1,052.8
Selling, marketing and administrative 182.7 186.9 571.7 551.9
Research and development 42.5 41.5 136.1 140.4
Amortization of intangible assets 50.8 47.7 146.6 143.6
Restructuring, integration and other charges 7.1 39.6 18.0 234.6
Goodwill impairment charge — 700.7 — 700.7
Asset impairment charge 12.5 9.7 12.5 9.7
Other operating expenses 1.5 14.3 2.5 25.8
Operating loss (7.5) (704.8) (61.1) (852.9)
Interest expense, net 55.4 46.1 161.2 126.6
Loss on extinguishment of debt — 5.1 — 5.1
Other expense, net — 0.9 1.3 10.7
Loss before income taxes (62.9) (756.9) (223.6) (995.3)
(Benefit from) provision for income taxes (9.1) (23.9) 14.9 5.8
Net loss $        (53.8) $       (733.0) $       (238.5) $    (1,001.1)
Basic loss per share $        (0.78) $       (10.78) $        (3.49) $       (14.79)
Diluted loss per share $        (0.78) $       (10.78) $        (3.49) $       (14.79)
Weighted-average shares outstanding - basic 68.7 68.0 68.4 67.7
Weighted-average shares outstanding - diluted 68.7 68.0 68.4 67.7
**QuidelOrtho **Condensed Consolidated Balance Sheets (Unaudited) (In millions)
September 27, 2026 December 28, 2025
ASSETS
Current assets:
Cash and cash equivalents $              166.4 $              169.8
Accounts receivable, net 375.5 417.0
Inventories 642.7 577.6
Prepaid expenses and other current assets 241.5 250.5
Assets held for sale 19.9 32.4
Total current assets 1,446.0 1,447.3
Property, plant and equipment, net 1,323.6 1,358.3
Right-of-use assets 151.0 155.5
Intangible assets, net 2,628.3 2,563.8
Other assets 232.4 244.4
Total assets $            5,781.3 $            5,769.3
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $              253.3 $              279.4
Accrued payroll and related expenses 76.4 120.3
Income tax payable 3.3 11.5
Current portion of borrowings 424.4 178.3
Other current liabilities 309.7 376.6
Total current liabilities 1,067.1 966.1
Operating lease liabilities 146.9 154.4
Long-term borrowings 2,512.9 2,471.9
Deferred tax liabilities 121.5 90.0
Other liabilities 141.6 166.4
Total liabilities 3,990.0 3,848.8
Total stockholders' equity 1,791.3 1,920.5
Total liabilities and stockholders' equity $            5,781.3 $            5,769.3
**QuidelOrtho **Condensed Consolidated Statements of Cash Flows (Unaudited) (In millions)
Three Months Ended Nine Months Ended
September 27, 2026 September 28, 2025 September 27, 2026 September 28, 2025
Cash provided by (used for) operating activities $              19.6 $             (45.5) $           (124.0) $             (26.7)
Cash used for investing activities (20.9) (53.9) (162.2) (143.1)
Cash provided by financing activities 44.1 46.0 282.3 166.9
Effect of exchange rates on cash 0.2 (0.2) 0.5 2.5
Net increase (decrease) in cash, cash equivalents and restricted cash 43.0 (53.6) (3.4) (0.4)
Cash, cash equivalents and restricted cash at beginning of period 123.4 151.7 169.8 98.5
Cash, cash equivalents and restricted cash at end of period $            166.4 $              98.1 $            166.4 $              98.1
Free Cash Flow(a):
Cash provided by (used for) operating activities $              19.6 $             (45.5) $           (124.0) $             (26.7)
Less: Acquisitions of property, plant, equipment, investments and intangibles (capital expenditures) (20.4) (49.2) (80.5) (143.7)
Plus: Proceeds from sale of property, plant and equipment (capital disposals) 1.1 — 1.7 0.8
Free Cash Flow (non-GAAP) $                0.3 $             (94.7) $           (202.8) $           (169.6)
(a) We define free cash flow as operating cash flows, less payments for acquisitions of property, plant, equipment, investments and intangibles ("capital expenditures") plus the proceeds from sale of property, plant and equipment ("capital disposals").
**QuidelOrtho **Reconciliation of Non-GAAP Financial Information - Adjusted Net Income (In millions, except per share data; unaudited)
Three Months Ended Nine Months Ended
September 27, 2026 Diluted EPS September 28, 2025 Diluted EPS September 27, 2026 Diluted EPS September 28, 2025 Diluted EPS
Net loss $       (53.8) $     (0.78) $      (733.0) $    (10.78) $      (238.5) $     (3.49) $   (1,001.1) $    (14.79)
Adjustments:
Amortization of intangibles 50.8 47.7 146.6 143.6
Restructuring, integration and other charges 7.1 39.6 18.0 234.6
Goodwill impairment charge — 700.7 — 700.7
Asset impairment charge 12.5 9.7 12.5 9.7
Loss on extinguishment of debt — 5.1 — 5.1
Legal accrual — 9.4 — 9.4
Amortization of deferred cloud computing implementation costs 9.1 7.9 26.3 19.0
Employee compensation charges 3.7 — 13.7 —
Tax indemnification expense — — 3.3 —
Incremental depreciation on PP&E fair value adjustment 3.4 5.1 9.9 15.7
Accelerated depreciation 2.0 1.5 6.1 2.5
EU medical device regulation transition costs 0.2 0.2 1.6 0.5
Loss (gain) on investments — 0.6 9.0 (0.7)
Credit Agreement amendment fees 0.5 — 0.5 —
Other adjustments 2.8 2.6 14.3 4.6
Income tax impact of adjustments (17.1) (42.4) 4.7 (30.8)
Adjusted net income $         21.2 $      0.31 $         54.7 $      0.80 $         28.0 $      0.41 $       112.8 $      1.66
Weighted-average shares outstanding - diluted 69.1 68.1 68.7 68.0
**QuidelOrtho **Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA (In millions, unaudited)
Three Months Ended Nine Months Ended
September 27, 2026 September 28, 2025 September 27, 2026 September 28, 2025
Net loss $      (53.8) $     (733.0) $     (238.5) $  (1,001.1)
Depreciation and amortization 119.6 112.1 349.2 329.5
Interest expense, net 55.4 46.1 161.2 126.6
(Benefit from) provision for income taxes (9.1) (23.9) 14.9 5.8
Restructuring, integration and other charges 7.1 39.6 18.0 234.6
Goodwill impairment charge — 700.7 — 700.7
Asset impairment charge 12.5 9.7 12.5 9.7
Loss on extinguishment of debt — 5.1 — 5.1
Legal accrual — 9.4 — 9.4
Amortization of deferred cloud computing implementation costs 9.1 7.9 26.3 19.0
Employee compensation charges 3.7 — 13.7 —
Tax indemnification expense — — 3.3 —
EU medical device regulation transition costs 0.2 0.2 1.6 0.5
Loss (gain) on investments — 0.6 9.0 (0.7)
Credit Agreement amendment fees 0.5 — 0.5 —
Other adjustments 2.8 2.6 14.3 4.6
Adjusted EBITDA $      148.0 $      177.1 $      386.0 $      443.7
Total revenues $      618.9 $      699.9 $    1,869.6 $    2,006.6
Adjusted EBITDA margin 23.9 % 25.3 % 20.6 % 22.1 %
**QuidelOrtho **Reconciliation of Non-GAAP Financial Information - Revenues (In millions, unaudited)
Three Months Ended
September 27, 2026 September 28, 2025 % Change Currency Impact Constant Currency (a)
Labs $        353.2 $        373.8 (5.5) % 0.4 % (5.9) %
Immunohematology 142.0 142.0 — % (0.9) % 0.9 %
Donor Screening 1.7 14.7 (88.4) % — % (88.4) %
Point of Care 119.6 164.6 (27.3) % (0.1) % (27.2) %
Molecular Diagnostics 2.4 4.8 (50.0) % (0.7) % (49.3) %
Total revenues $        618.9 $        699.9 (11.6) % — % (11.6) %
Three Months Ended
September 27, 2026 September 28, 2025 % Change Currency Impact Constant Currency (a)
Total revenues $        618.9 $        699.9 (11.6) % — % (11.6) %
Respiratory 68.8 112.3 (38.7) % — % (38.7) %
China excluding respiratory 48.4 84.4 (42.7) % 3.2 % (45.9) %
U.S. Donor Screening 0.5 13.1 (96.0) % — % (96.0) %
Total revenues excluding respiratory, China, and U.S. Donor Screening $        501.2 $        490.1 2.3 % (0.7) % 3.0 %
Three Months Ended
September 27, 2026 September 28, 2025 % Change Currency Impact Constant Currency (a)
Labs $        353.2 $        373.8 (5.5) % 0.4 % (5.9) %
China Labs 36.9 67.7 (45.5) % 3.2 % (48.7) %
Total Labs revenues excluding China $        316.3 $        306.1 3.3 % (0.5) % 3.8 %
(a) The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.
Three Months Ended
September 27, 2026 September 28, 2025 % Change Currency Impact Constant Currency (a)
Immunohematology $        142.0 $        142.0 — % (0.9) % 0.9 %
China Immunohematology 8.0 10.2 (21.6) % 4.1 % (25.7) %
Total Immunohematology revenues excluding China $        134.0 $        131.8 1.7 % (1.3) % 3.0 %
(a) The term "constant currency" means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-reports-third-quarter-2026-financial-results-302928073.html

SOURCE QuidelOrtho Corporation

Categories: Press Releases

View all news

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At QuidelOrtho Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to QuidelOrtho Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events
SEC Filings
Annual Reports
Financial Report

Submit Sign Up

Email Alert Sign Up Confirmation

Investor Contact

Sanjeev Sharma

QuidelOrtho

Vice President, Investor Relations

[email protected]

Transfer Agent

Website: www.computershare.com
Telephone inquiries: 1-800-736-3001, option 1 (U.S.) 1-781-575-3100, option 1 (non-U.S.)
E-mail inquiries: [email protected]

Copyright © 2025 QuidelOrtho Corporation. All rights reserved.

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

10/29/2026

Download this Press Release PDF Format (opens in new window)

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother. 

Rodney Guzman, Vice President of Software Engineering for Global Informatics Platforms, QuidelOrtho

Laboratories are facing increasing complexity and growing testing demand. Historically, data across the lab has existed in silos. Labs need ways to integrate this data and accelerate clinical decision-making. Informatics serves as a critical means to drive efficiency, performance and data accuracy – having a real impact on patients awaiting test results.

Hosted by Josh Casey, this episode features QuidelOrtho's Vice President of Software Engineering for Global Informatics Platforms, Rodney Guzman, who illustrates how to apply structured informatics to transform results from discrete laboratory systems into meaningful clinical knowledge.

Key Insights:

  • Clinical laboratories face workforce challenges, including shortages of specialists to manage complex testing scenarios
  • AI has the potential to optimize test utilization, eliminate redundant testing and reduce workflow bottlenecks
  • However, before this happens, the underlying lab data must be standardized, reliable and traceable; otherwise, the AI system can't deliver reliable insights
  • Informatics serves as a means to consolidate, organize and present data sets consistently
  • Integrating this data is particularly beneficial for supporting applications like transfusion medicine where a complex array of data influences clinical decisions
  • In any lab setting, AI augments clinical experts, and lab professionals are ultimately responsible for interpreting results and making final decisions

Listen to the latest episode of the QuidelOrtho Science Bytes podcast on major streaming platforms or at https://www.quidelortho.com/global/en/resources/podcasts/Episode-62-Turning-results-into-answers .

Investor Contact:
Sanjeev Sharma
Vice President, Investor Relations
[email protected]  

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
[email protected]  

QuidelOrtho Corporation

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transforming-data-into-actionable-insights-in-the-lab-302923957.html

SOURCE QuidelOrtho Corporation

Categories: Press Releases

View all news

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At QuidelOrtho Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to QuidelOrtho Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events
SEC Filings
Annual Reports
Financial Report

Submit Sign Up

Email Alert Sign Up Confirmation

Investor Contact

Sanjeev Sharma

QuidelOrtho

Vice President, Investor Relations

[email protected]

Transfer Agent

Website: www.computershare.com
Telephone inquiries: 1-800-736-3001, option 1 (U.S.) 1-781-575-3100, option 1 (non-U.S.)
E-mail inquiries: [email protected]

Copyright © 2025 QuidelOrtho Corporation. All rights reserved.

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Prompts

QuidelOrtho Corporation (ticker QDEL), listed in United States.

Company History

Date Change Detail
May 27, 2022 Renamed Coronado Topco, Inc. → QUIDELORTHO CORP
Jan 31, 2022 Renamed QUIDEL CORP /DE/ → Coronado Topco, Inc.

ETFs Holding QuidelOrtho Corporation

ETF Weight in ETF Shares Market value As of
MGMT 0.99% 101,008 $ 1.769M Jun 30, 2026
EHLS short -0.71% -37,279 $ -380.619K Nov 17, 2026
FFSM 0.19% 169,647 $ 2.845M Jul 31, 2026
MSSM 0.15% 76,216 $ 1.1M Aug 31, 2026
AVUV 0.12% 3,717,883 $ 37.96M Nov 16, 2026
SCDS 0.11% 973 $ 9,603.51 Nov 17, 2026
FSCC 0.11% 27,612 $ 398.441K Aug 31, 2026
MCDS 0.06% 457 $ 4,510.59 Nov 17, 2026
BSVO 0.06% 146,698 $ 1.45M Nov 18, 2026
RESM 0.06% 116 $ 2,031.74 Jun 30, 2026
AVSC 0.04% 125,879 $ 1.285M Nov 16, 2026
JMEE 0.03% 87,763 $ 866.221K Nov 17, 2026
DFSV 0.01% 345,086 $ 3.665M Nov 12, 2026
AVSU 0.01% 2,807 $ 28.659K Nov 16, 2026
DFAT 0.00% 148,267 $ 1.575M Nov 12, 2026
DFAS 0.00% 30,210 $ 320.83K Nov 12, 2026
DXUV 0.00% 3,538 $ 37.574K Nov 12, 2026
DFUS 0.00% 7,740 $ 82.199K Nov 12, 2026
DFAU 0.00% 1,784 $ 18.946K Nov 12, 2026
DFAC 0.00% 1,979 $ 21.017K Nov 12, 2026
DCOR 0.00% 644 $ 6,839.28 Nov 12, 2026
AVUS 0.00% 48,038 $ 490.468K Nov 16, 2026